LOCHOLEST Drug Patent Profile

« Back to Dashboard

When do Locholest patents expire, and when can generic versions of Locholest launch?

Locholest is a drug marketed by Chartwell Rx and is included in two NDAs.

The generic ingredient in LOCHOLEST is cholestyramine. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the cholestyramine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Locholest

A generic version of LOCHOLEST was approved as cholestyramine by EPIC PHARMA LLC on August 15^th, 1996.

Summary for LOCHOLEST

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
DailyMed Link:	LOCHOLEST at DailyMed

Pharmacology for LOCHOLEST

Drug Class	Bile Acid Sequestrant
Mechanism of Action	Bile-acid Binding Activity

US Patents and Regulatory Information for LOCHOLEST

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	LOCHOLEST	cholestyramine	POWDER;ORAL	074561-001	Aug 15, 1996	AB	RX	No	No
Chartwell Rx	LOCHOLEST LIGHT	cholestyramine	POWDER;ORAL	074562-002	Aug 15, 1996	AB	RX	No	No
Chartwell Rx	LOCHOLEST	cholestyramine	POWDER;ORAL	074561-002	Aug 15, 1996	AB	RX	No	No
Chartwell Rx	LOCHOLEST LIGHT	cholestyramine	POWDER;ORAL	074562-001	Aug 15, 1996	AB	RX	No	No

LOCHOLEST Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 13, 2026

LOCHOLEST is a cholestyramine oral powder product used primarily to reduce elevated LDL cholesterol. Its commercial position is structurally weak because cholestyramine has been generic for decades, has no meaningful remaining patent exclusivity, and competes with generic cholestyramine, colesevelam, colestipol, statins, ezetimibe, and PCSK9 therapies. LOCHOLEST’s principal commercial value is in residual prescription demand, product familiarity, and niche use in bile acid-related disorders rather than in protected pricing power.

Public disclosures do not report LOCHOLEST-specific revenue. The product’s financial trajectory is therefore best assessed through regulatory status, generic competition, prescription utility, channel access, and the economics of its private-label or branded distribution.

What is LOCHOLEST and how does it work?

LOCHOLEST is a branded formulation of cholestyramine, a nonabsorbed bile acid sequestrant supplied as an oral powder for suspension. Cholestyramine binds bile acids in the intestinal tract and prevents their reabsorption. The liver then uses circulating cholesterol to synthesize replacement bile acids, reducing LDL cholesterol.

The product’s FDA-approved use is as an adjunct to diet for reducing elevated serum cholesterol and the risk associated with hypercholesterolemia. The label also identifies use in patients with primary hypercholesterolemia who do not respond adequately to diet alone. [1]

LOCHOLEST product profile

Attribute	LOCHOLEST
Active ingredient	Cholestyramine
Dosage form	Oral powder for suspension
Typical strength	4-gram cholestyramine dose per packet or measure
Drug class	Bile acid sequestrant
Route	Oral
Absorption	Minimally or not systemically absorbed
Primary FDA use	Adjunctive LDL-cholesterol reduction
Original regulatory era	1970s-era cholestyramine market
Current patent protection	No material active composition-of-matter protection
Biosimilar exposure	None
Main substitutes	Generic cholestyramine, colesevelam, colestipol, statins, ezetimibe, PCSK9 therapies

LOCHOLEST and LOCHOLEST Light have historically been differentiated through formulation, taste, packaging, and powder presentation rather than through a new molecular entity or a clinically distinct mechanism.

What is the FDA regulatory status of LOCHOLEST?

LOCHOLEST is associated with an older FDA-approved cholestyramine product and has been marketed in the United States under the prescription-drug framework. FDA labeling identifies cholestyramine for oral suspension as the relevant dosage form and active ingredient. [1]

The practical commercial issue is whether a particular LOCHOLEST presentation remains actively marketed and broadly distributed. Older branded products can remain listed in historical FDA and labeling databases while experiencing limited or intermittent commercial availability. Product availability may differ by package size, distributor, wholesaler, and pharmacy benefit channel.

Does LOCHOLEST have FDA exclusivity?

No meaningful FDA regulatory exclusivity remains commercially relevant for LOCHOLEST.

Cholestyramine’s underlying approval predates modern periods of orphan-drug, pediatric, and new-chemical-entity exclusivity. The product is also not a biologic and does not receive biosimilar reference-product exclusivity. Any residual brand value comes from commercial recognition or distribution, not from FDA exclusivity.

What patents protect LOCHOLEST?

No active patent estate appears to provide LOCHOLEST with meaningful market protection.

Patent protection by category

Patent category	LOCHOLEST position	Commercial effect
Composition-of-matter patent	Expired or unavailable for commercial reliance	No protection
New chemical entity exclusivity	Not applicable to this legacy product	No protection
Formulation patent	No material current barrier identified	Limited or no protection
Method-of-use patent	No material current barrier identified	Limited or no protection
Manufacturing patent	No publicly established barrier that would block generic supply	Limited or no protection
Orange Book patent listing	No material active listing identified in current commercial analysis	Generic competition remains open

Cholestyramine is a mature resin product. Any historic patents covering the active ingredient, basic dosage form, or early manufacturing processes would have expired long ago. A later formulation patent could theoretically affect a specific powder, flavor, excipient, or delivery system, but no such patent appears to create a defensible commercial moat for LOCHOLEST.

When does LOCHOLEST lose exclusivity?

LOCHOLEST effectively lost exclusivity decades ago.

The relevant competitive event was not a recent patent expiry but the maturation of cholestyramine as a generic active ingredient. Generic cholestyramine products have been available for many years, and the market has also developed alternative bile acid sequestrants with different dosing and tolerability profiles.

Milestone	Approximate timing	Market impact
Cholestyramine approved for clinical use	1970s	Established the bile acid sequestrant class
Generic development	Following expiration of early protections	Opened price competition
Statin expansion	1990s onward	Reduced use of bile acid sequestrants for routine LDL treatment
Colesevelam adoption	2000s onward	Added a better-tolerated oral alternative
Current market	Mature and price-sensitive	Brand differentiation is limited

How many patents cover LOCHOLEST?

No material active patents have been identified as covering the commercial LOCHOLEST product in a way that would block generic entry.

The absence of meaningful patent protection is more important than the precise count. For a mature generic product, the relevant questions are whether a patent is listed for the reference product, whether an ANDA applicant must certify against it, and whether a court injunction could delay launch. LOCHOLEST does not appear to present those barriers at a commercially significant level.

Are there Paragraph IV challenges to LOCHOLEST?

No major current Paragraph IV litigation involving LOCHOLEST has been identified in the public record used for this analysis.

Paragraph IV litigation is generally associated with a listed patent protecting an innovator product. Because LOCHOLEST has no apparent active patent barrier of commercial significance, the product is more exposed to ordinary generic competition than to a new wave of patent litigation.

The competitive risk is therefore based on:

1. Generic price substitution.
2. Wholesaler and pharmacy formulary decisions.
3. Product discontinuation or supply interruptions.
4. Substitution by other lipid-lowering therapies.
5. Declining clinical preference for powder-based bile acid sequestrants.

What formulations are protected by LOCHOLEST?

LOCHOLEST’s formulation differentiation is commercially modest.

The product is an oral powder that must be mixed with liquid or soft food before administration. That creates adherence and tolerability problems compared with tablets and newer agents. The formulation may use different flavoring, particle characteristics, packaging, or excipients than competing cholestyramine products, but these attributes generally do not create durable market exclusivity.

Formulation strengths and weaknesses

Factor	Commercial implication
Powder dosage form	Lower convenience than tablets
Nonabsorbed mechanism	Useful when systemic exposure is undesirable
Drug-interaction binding	Requires separation from many oral medicines
Taste and texture	Can reduce adherence
Low manufacturing complexity	Supports generic competition
Long clinical history	Supports physician familiarity
Low price	Preserves use in cost-sensitive channels

The dosage form remains clinically relevant in selected patients, including those who cannot tolerate statins or who require bile acid binding for non-lipid indications. Its limitations prevent broad expansion in the mainstream dyslipidemia market.

What is the competitive landscape for LOCHOLEST?

LOCHOLEST competes in two separate markets.

The first is LDL reduction. In this market, statins are the dominant low-cost therapy. Ezetimibe offers oral nonstatin treatment, while PCSK9 inhibitors and inclisiran address higher-risk or treatment-resistant patients. Cholestyramine is generally a secondary or adjunctive option.

The second is bile acid sequestration for bile acid-related gastrointestinal or dermatologic conditions. Use in bile acid diarrhea and cholestatic pruritus is clinically recognized but often occurs outside the product’s core FDA-approved lipid indication. This niche can preserve demand even when routine hypercholesterolemia use declines.

Competitor	Class	Competitive position
Generic cholestyramine	Same active ingredient	Direct price substitute
Prevalite and other cholestyramine brands	Same active ingredient	Brand and distribution competition
Colestipol	Bile acid sequestrant	Alternative resin product
Colesevelam	Newer bile acid sequestrant	Better tablet convenience and tolerability
Atorvastatin and rosuvastatin	Statins	First-line LDL-lowering alternatives
Ezetimibe	Cholesterol absorption inhibitor	Oral nonstatin substitute
PCSK9 inhibitors	Biologic lipid-lowering agents	High-efficacy option for selected patients

How strong is the LOCHOLEST patent estate?

The patent estate is weak.

A strong pharmaceutical patent estate usually combines composition, formulation, manufacturing, method-of-use, and pediatric or orphan exclusivity. LOCHOLEST lacks that combination. Its commercial protection is primarily operational:

• Product availability.
• Distributor relationships.
• Pharmacy stocking.
• Familiarity among prescribers.
• Potentially favorable reimbursement for a low-cost product.
• Ability to maintain consistent flavor and package performance.

These factors can support a residual brand business but do not prevent substitution.

What patent litigation affects LOCHOLEST?

No material active patent litigation has been identified as a current driver of LOCHOLEST’s market value.

The product is unlikely to generate the type of litigation seen with protected specialty drugs. There is no apparent branded-versus-generic settlement structure comparable to products with high-value Orange Book patents. Litigation risk is more likely to arise from manufacturing quality, supply, labeling, or commercial contracting than from patent enforcement.

What is the financial trajectory of LOCHOLEST?

LOCHOLEST’s financial trajectory is likely flat to declining in branded terms, with periodic resilience from niche demand.

The product faces three revenue pressures:

1. Generic substitution compresses net price.
2. Statins and newer nonstatins reduce use in primary lipid management.
3. Powder administration limits adherence and market expansion.

The product retains several defensive characteristics. Cholestyramine is inexpensive, clinically familiar, nonabsorbed, and useful in patients who cannot use or tolerate other therapies. It can also be used in treatment contexts where bile acid binding is the clinical objective rather than LDL reduction.

Revenue exposure

No public company disclosure identifies standalone LOCHOLEST sales, prescription volume, gross margin, or operating profit. Upsher-Smith, historically associated with the product, has operated within broader portfolio structures, and product-level financial data are not publicly separated. ANI Pharmaceuticals acquired Upsher-Smith in 2019, but ANI’s public reporting does not provide a distinct LOCHOLEST revenue line. [2]

Accordingly, LOCHOLEST should be classified as a low-transparency, mature-product asset rather than as a separately valued growth franchise.

Financial scenario analysis

Scenario	Likely outcome
Base case	Low, stable-to-declining revenue from residual prescriptions
Downside case	Accelerated erosion from generic substitution or product discontinuation
Upside case	Temporary demand increase from shortages, formulary preference, or niche bile acid use
Strategic value	Portfolio filler with modest cash generation, not a platform asset
Licensing value	Limited unless tied to manufacturing, distribution, or a differentiated formulation

What generic entry risks exist for LOCHOLEST?

Generic entry risk is already realized rather than prospective.

The commercial threat is ongoing generic substitution. A generic manufacturer does not need to overcome a novel mechanism or complex delivery system. Cholestyramine is a mature, nonabsorbed resin with established manufacturing knowledge. The principal barriers are product quality, powder uniformity, taste, packaging, supply reliability, and regulatory compliance.

Generic launch scenarios

A new generic entrant could gain share by offering:

• Lower acquisition cost.
• Reliable wholesaler supply.
• Preferred Medicaid or commercial formulary placement.
• Improved flavor or package convenience.
• Smaller or more flexible package sizes.
• Consistent availability during branded or competing-product shortages.

A generic entrant would face limited patent litigation risk but could encounter practical challenges in demonstrating acceptable product quality and maintaining supply economics in a low-price market.

What licensing deals affect LOCHOLEST?

No material LOCHOLEST-specific licensing transaction has been publicly disclosed that changes the product’s competitive position.

The most relevant corporate transaction is ANI Pharmaceuticals’ acquisition of Upsher-Smith. That transaction transferred a broader portfolio of generic and branded pharmaceutical assets, rather than creating a LOCHOLEST-specific licensing moat. [2]

Potential strategic value would come from bundling LOCHOLEST with other primary-care or gastrointestinal products, using an established distribution platform, or retaining supply in a shortage-prone niche. A standalone licensing transaction would likely command limited value because the product lacks exclusivity and public revenue transparency.

What is the geographic coverage of LOCHOLEST?

LOCHOLEST’s principal commercial relevance is the United States. The product’s FDA history and U.S. prescription positioning are more commercially important than international patent coverage.

Cholestyramine is marketed under different brands and generic names in multiple jurisdictions, but international market value depends on local registration, reimbursement, manufacturing, and distribution. Expired U.S. exclusivity does not establish a protected global position.

Key Takeaways

• LOCHOLEST is a legacy cholestyramine oral powder product.
• Its patent and regulatory exclusivity have effectively expired.
• No material active patent estate or current Paragraph IV litigation drives its value.
• Generic cholestyramine is the primary direct competitor.
• Statins, ezetimibe, colesevelam, colestipol, and PCSK9 therapies limit growth.
• The product retains niche value in bile acid-related use and in patients who cannot tolerate other lipid-lowering drugs.
• No public source reports standalone LOCHOLEST revenue.
• The likely financial profile is low-margin, mature, and stable to declining, with occasional supply-driven upside.
• Manufacturing consistency, distribution, and formulary access matter more than intellectual property.

FAQs About LOCHOLEST

Is LOCHOLEST still commercially available?

Availability can vary by package size, distributor, and pharmacy inventory. Historical FDA labeling does not guarantee continuous broad-market distribution.

Is LOCHOLEST the same as cholestyramine?

Yes. LOCHOLEST is a branded cholestyramine oral powder product. Generic cholestyramine provides the closest direct substitute.

Can LOCHOLEST be used for bile acid diarrhea?

Cholestyramine is widely used in clinical practice for bile acid diarrhea, but that use is generally distinct from the product’s core FDA-approved cholesterol indication.

Does LOCHOLEST have a biosimilar competitor?

No. LOCHOLEST is a conventional small-molecule-derived resin product, not a biologic. Its competitors are generic and therapeutic substitutes rather than biosimilars.

Is LOCHOLEST an attractive licensing or acquisition target?

Only as a small portfolio asset with established demand, low manufacturing complexity, or distribution synergies. Its lack of exclusivity and undisclosed standalone revenue limit strategic valuation.

References

1. U.S. Food and Drug Administration. (n.d.). LOCHOLEST- cholestyramine powder, for suspension: Prescribing information. DailyMed.
2. ANI Pharmaceuticals, Inc. (2019). ANI Pharmaceuticals completes acquisition of the U.S. specialty and generic pharmaceutical business of Upsher-Smith Laboratories. Corporate transaction announcement.